Abstract
Epidemics caused by microbial organisms are part of the natural phenomena of increasing biological complexity. The heterogeneity and constant variability of hosts, in terms of age, immunological status, family structure, lifestyle, work activities, social and leisure habits, daily division of time, and other demographic characteristics make it extremely difficult to predict the evolution of epidemics. Such prediction is, however, critical for implementing intervention measures in due time and with appropriate intensity. General conclusions should be precluded, given that local parameters dominate the flow of local epidemics. Membrane computing models allows us to reproduce the objects (viruses, hosts) and their interactions (stochastic but also with defined probabilities) with an unprecedented level of detail. Our LOIMOS model helps reproduce the demographics and social aspects of a hypothetical town of 10,320 inhabitants in an average European country where COVID-19 is imported from the outside. The above-mentioned characteristics of hosts and their lifestyle are minutely considered. The dynamics of the epidemics are reproduced and include the effects on viral transmission of innate and acquired immunity at various ages. The model predicts the consequences of delaying the adoption of non-pharmaceutical interventions (between 15 and 45 days after the first reported cases) and the effect of those interventions on infection and mortality rates (reducing transmission by 20%, 50%, and 80%) in immunological response groups. The lockdown for the elderly population as a single intervention appears to be effective. This modelling exercise exemplifies the application of membrane computing for designing appropriate interventions in epidemic situations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MC and FB were sponsored by the Projects COV20_00067 of the Program SARS-COV-2 and COVID-19 infection of the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion of Spain, CB06/02/0053 of the Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica (CIBERESP), and the Regional Government of Madrid (InGeMICS-B2017/BMD-3691). For JCG, this study was partially founded by the Autonomous Community of Madrid, Spain (COVID-19 Grant, 2020) and the Ramon y Cajal Institute for Health Research (IRYCIS), Madrid, Spain. For AM, this study was supported by grants from the Spanish Ministry of Science and Innovation (PID2019-105969GB-I00), the government of Valencia (project Prometeo/2018/A/133) and co-financed by the European Regional Development Fund (ERDF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is an in-silico work, not involving human or animal individuals.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data obtained are freely public; in that concernng the accessibility of the model interface, please examine the manuscript.